DE60013147T2 - Caspase-hemmer - Google Patents
Caspase-hemmer Download PDFInfo
- Publication number
- DE60013147T2 DE60013147T2 DE60013147T DE60013147T DE60013147T2 DE 60013147 T2 DE60013147 T2 DE 60013147T2 DE 60013147 T DE60013147 T DE 60013147T DE 60013147 T DE60013147 T DE 60013147T DE 60013147 T2 DE60013147 T2 DE 60013147T2
- Authority
- DE
- Germany
- Prior art keywords
- carbonylamino
- methyl
- propyl
- dihydro
- isoxazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108010076667 Caspases Proteins 0.000 title claims abstract description 69
- 102000011727 Caspases Human genes 0.000 title claims abstract description 68
- 239000003112 inhibitor Substances 0.000 title description 26
- 238000006243 chemical reaction Methods 0.000 claims abstract description 38
- 150000002547 isoxazolines Chemical class 0.000 claims abstract description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 24
- 201000010099 disease Diseases 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 208000006454 hepatitis Diseases 0.000 claims abstract description 19
- 150000002148 esters Chemical class 0.000 claims abstract description 18
- 231100000283 hepatitis Toxicity 0.000 claims abstract description 18
- 238000002054 transplantation Methods 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 206010012289 Dementia Diseases 0.000 claims abstract description 7
- 206010061218 Inflammation Diseases 0.000 claims abstract description 7
- 206010040047 Sepsis Diseases 0.000 claims abstract description 7
- 208000007107 Stomach Ulcer Diseases 0.000 claims abstract description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 6
- 210000000056 organ Anatomy 0.000 claims abstract description 6
- 208000030507 AIDS Diseases 0.000 claims abstract description 5
- 201000005917 gastric ulcer Diseases 0.000 claims abstract description 5
- 230000004054 inflammatory process Effects 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 214
- -1 ethanesulfonyl Chemical group 0.000 claims description 179
- 239000000203 mixture Substances 0.000 claims description 96
- 230000006907 apoptotic process Effects 0.000 claims description 66
- 210000004027 cell Anatomy 0.000 claims description 48
- 238000011282 treatment Methods 0.000 claims description 37
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 30
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 18
- 238000002347 injection Methods 0.000 claims description 17
- 239000007924 injection Substances 0.000 claims description 17
- 229940123169 Caspase inhibitor Drugs 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 230000004913 activation Effects 0.000 claims description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 11
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 208000007788 Acute Liver Failure Diseases 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 150000001721 carbon Chemical group 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- SGHANKVVISIETA-NUUXIFOFSA-N (3s)-3-[[5-benzyl-3-[(1s)-1-(1h-indole-2-carbonylamino)-2-methylpropyl]-4h-1,2-oxazole-5-carbonyl]amino]-5-(2,6-dichlorobenzoyl)oxy-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2NC3=CC=CC=C3C=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)CC1=CC=CC=C1 SGHANKVVISIETA-NUUXIFOFSA-N 0.000 claims description 6
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Natural products CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 6
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 6
- JKKFMABMEODGRO-TYNJXUSYSA-N (3s)-3-[[5-benzyl-3-[(1s)-1-(1h-indole-3-carbonylamino)-2-methylpropyl]-4h-1,2-oxazole-5-carbonyl]amino]-5-(2,6-dichlorobenzoyl)oxy-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2C3=CC=CC=C3NC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)CC1=CC=CC=C1 JKKFMABMEODGRO-TYNJXUSYSA-N 0.000 claims description 5
- QYZMOSOGHHPYDR-MIQQLYACSA-N (3s)-5-(2,6-dichlorobenzoyl)oxy-3-[[5-methyl-3-[(1s)-2-methyl-1-(naphthalene-1-carbonylamino)propyl]-4h-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)C1(C)ON=C(C1)[C@@H](NC(=O)C=1C2=CC=CC=C2C=CC=1)C(C)C)COC(=O)C1=C(Cl)C=CC=C1Cl QYZMOSOGHHPYDR-MIQQLYACSA-N 0.000 claims description 5
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 5
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- JUKMFKWQUZNAMJ-SFQDAYOWSA-N (3s)-3-[[3-[(1s)-2-methyl-1-(phenylmethoxycarbonylamino)propyl]-5-(phenoxymethyl)-4h-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound N([C@@H](C(C)C)C=1CC(COC=2C=CC=CC=2)(ON=1)C(=O)N[C@@H](CC(O)=O)C(C)=O)C(=O)OCC1=CC=CC=C1 JUKMFKWQUZNAMJ-SFQDAYOWSA-N 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims description 4
- 150000001923 cyclic compounds Chemical class 0.000 claims description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 4
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 4
- 229930192474 thiophene Natural products 0.000 claims description 4
- AMIBKSPSWDLSAW-JERZPMBSSA-N (3s)-3-[[3-[(1s)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-4,5-dihydro-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound C1([C@@H](NC(=O)C=2C=C3C=CC=CC3=CC=2)C(C)C)=NOC(C(=O)N[C@@H](CC(O)=O)C(C)=O)C1 AMIBKSPSWDLSAW-JERZPMBSSA-N 0.000 claims description 3
- QNIUHMFSURKYFW-ZRHIXDKOSA-N (3s)-3-[[3-[(1s)-2-methyl-1-(phenylmethoxycarbonylamino)propyl]-4,5-dihydro-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound N([C@@H](C(C)C)C=1CC(ON=1)C(=O)N[C@@H](CC(O)=O)C(C)=O)C(=O)OCC1=CC=CC=C1 QNIUHMFSURKYFW-ZRHIXDKOSA-N 0.000 claims description 3
- XHPWBJPWEBWAKH-UMQIIANQSA-N (3s)-3-[[3-[(1s)-2-methyl-1-(quinoline-2-carbonylamino)propyl]-4,5-dihydro-1,2-oxazole-5-carbonyl]amino]-4-oxo-5-phenoxypentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)C1ON=C(C1)[C@@H](NC(=O)C=1N=C2C=CC=CC2=CC=1)C(C)C)COC1=CC=CC=C1 XHPWBJPWEBWAKH-UMQIIANQSA-N 0.000 claims description 3
- PIRHZWPTWBUUOY-HVZFRMHZSA-N (3s)-3-[[5-benzyl-3-[(1s)-2-methyl-1-(3-phenylprop-2-enoylamino)propyl]-4h-1,2-oxazole-5-carbonyl]amino]-5-(2,6-dichlorobenzoyl)oxy-4-oxopentanoic acid Chemical compound N([C@@H](C(C)C)C=1CC(CC=2C=CC=CC=2)(ON=1)C(=O)N[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)C(=O)C=CC1=CC=CC=C1 PIRHZWPTWBUUOY-HVZFRMHZSA-N 0.000 claims description 3
- VWTNLBJARJITTF-YXBGZAQISA-N (3s)-3-[[5-benzyl-3-[(1s)-2-methyl-1-(quinoline-8-carbonylamino)propyl]-4h-1,2-oxazole-5-carbonyl]amino]-5-(2,6-dichlorobenzoyl)oxy-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2C3=NC=CC=C3C=CC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)CC1=CC=CC=C1 VWTNLBJARJITTF-YXBGZAQISA-N 0.000 claims description 3
- ZNBNYEUEHILAPB-ALVJRTDLSA-N (3s)-5-(2,6-dichlorobenzoyl)oxy-3-[[3-[(1s)-2-methyl-1-(phenylmethoxycarbonylamino)propyl]-4,5-dihydro-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound N([C@@H](C(C)C)C=1CC(ON=1)C(=O)N[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)C(=O)OCC1=CC=CC=C1 ZNBNYEUEHILAPB-ALVJRTDLSA-N 0.000 claims description 3
- WTAJUWQGBFCFJD-SXVPRHBSSA-N (3s)-5-(2,6-dichlorobenzoyl)oxy-3-[[3-[(1s)-2-methyl-1-(quinoline-2-carbonylamino)propyl]-4,5-dihydro-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)C1ON=C(C1)[C@@H](NC(=O)C=1N=C2C=CC=CC2=CC=1)C(C)C)COC(=O)C1=C(Cl)C=CC=C1Cl WTAJUWQGBFCFJD-SXVPRHBSSA-N 0.000 claims description 3
- 206010000804 Acute hepatic failure Diseases 0.000 claims description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000004185 ester group Chemical group 0.000 claims description 3
- AMIUCRNGFBJBIT-VMZLPSRASA-N (3S)-3-[[5-benzyl-3-[(1S)-1-[[2-(1H-indol-3-yl)acetyl]amino]-2-methylpropyl]-4H-1,2-oxazole-5-carbonyl]amino]-5-diazo-4-oxopentanoic acid Chemical compound CC([C@H](NC(=O)CC1=CNC2=CC=CC=C12)C1=NOC(C1)(C(=O)N[C@@H](CC(=O)O)C(C=[N+]=[N-])=O)CC1=CC=CC=C1)C AMIUCRNGFBJBIT-VMZLPSRASA-N 0.000 claims description 2
- LYBOETQAQKFHRN-UCWKTWOXSA-N (3S)-3-[[5-benzyl-3-[(1S)-2-methyl-1-(3-phenylprop-2-enoylamino)propyl]-4H-1,2-oxazole-5-carbonyl]amino]-5-diazo-4-oxopentanoic acid Chemical compound CC(C)[C@H](NC(=O)C=Cc1ccccc1)C1=NOC(Cc2ccccc2)(C1)C(=O)N[C@@H](CC(O)=O)C(=O)C=[N+]=[N-] LYBOETQAQKFHRN-UCWKTWOXSA-N 0.000 claims description 2
- IJQDRCQHTQFVRO-OZIHFDBSSA-N (3S)-5-diazo-3-[[3-[(1S)-2-methyl-1-(phenylmethoxycarbonylamino)propyl]-4,5-dihydro-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound CC(C)[C@H](NC(=O)OCc1ccccc1)C1=NOC(C1)C(=O)N[C@@H](CC(O)=O)C(=O)C=[N+]=[N-] IJQDRCQHTQFVRO-OZIHFDBSSA-N 0.000 claims description 2
- BROGERWWRDQCLC-NUOXSBERSA-N (3S)-5-diazo-3-[[3-[(1S)-2-methyl-1-(quinoline-2-carbonylamino)propyl]-4,5-dihydro-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound C1([C@@H](NC(=O)C=2N=C3C=CC=CC3=CC=2)C(C)C)=NOC(C(=O)N[C@@H](CC(O)=O)C(=O)C=[N+]=[N-])C1 BROGERWWRDQCLC-NUOXSBERSA-N 0.000 claims description 2
- PTQUKSDULXNXDR-MJLQIQFDSA-N (3S)-5-diazo-3-[methyl-[3-[(1S)-2-methyl-1-(naphthalen-1-ylsulfonylamino)propyl]-5-phenyl-4H-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound CC(C)[C@H](NS(=O)(=O)c1cccc2ccccc12)C1=NOC(C1)(C(=O)N(C)[C@@H](CC(O)=O)C(=O)C=[N+]=[N-])c1ccccc1 PTQUKSDULXNXDR-MJLQIQFDSA-N 0.000 claims description 2
- OHHNYOJLWDPOSS-RXKSKBTASA-N (3S)-5-diazo-3-[methyl-[3-[(1S)-2-methyl-1-(naphthalene-1-carbonylamino)propyl]-5-phenyl-4H-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound CC(C)[C@H](NC(=O)c1cccc2ccccc12)C1=NOC(C1)(C(=O)N(C)[C@@H](CC(O)=O)C(=O)C=[N+]=[N-])c1ccccc1 OHHNYOJLWDPOSS-RXKSKBTASA-N 0.000 claims description 2
- UDKCKQILALRKRO-XOQPTCEHSA-N (3s)-3-[[3-[(1s)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-5-(phenoxymethyl)-4h-1,2-oxazole-5-carbonyl]amino]-4-oxo-5-phenoxypentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2C=C3C=CC=CC3=CC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)COC=1C=CC=CC=1)COC1=CC=CC=C1 UDKCKQILALRKRO-XOQPTCEHSA-N 0.000 claims description 2
- WECVYUDZYICKDV-NXUCYVCNSA-N (3s)-3-[[3-[(1s)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-5-(phenoxymethyl)-4h-1,2-oxazole-5-carbonyl]amino]-5-naphthalen-1-yloxy-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2C=C3C=CC=CC3=CC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)COC=1C2=CC=CC=C2C=CC=1)COC1=CC=CC=C1 WECVYUDZYICKDV-NXUCYVCNSA-N 0.000 claims description 2
- BFAKORDSYJJDDO-SNXXJJMMSA-N (3s)-3-[[3-[(1s)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-5-(phenoxymethyl)-4h-1,2-oxazole-5-carbonyl]amino]-5-naphthalen-2-yloxy-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2C=C3C=CC=CC3=CC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)COC=1C=C2C=CC=CC2=CC=1)COC1=CC=CC=C1 BFAKORDSYJJDDO-SNXXJJMMSA-N 0.000 claims description 2
- XVXKVVGJBYDHLE-HXVHBBJOSA-N (3s)-3-[[3-[(1s)-2-methyl-1-(quinoline-2-carbonylamino)propyl]-5-(phenoxymethyl)-4h-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2N=C3C=CC=CC3=CC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(C)=O)COC1=CC=CC=C1 XVXKVVGJBYDHLE-HXVHBBJOSA-N 0.000 claims description 2
- FGUQVUCZQOFWFW-KUVJNVSYSA-N (3s)-3-[[3-[(1s)-3-carboxy-1-(naphthalene-2-carbonylamino)propyl]-5-methyl-4h-1,2-oxazole-5-carbonyl]amino]-4-oxo-5-phenoxypentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)C1(ON=C(C1)[C@H](CCC(O)=O)NC(=O)C=1C=C2C=CC=CC2=CC=1)C)COC1=CC=CC=C1 FGUQVUCZQOFWFW-KUVJNVSYSA-N 0.000 claims description 2
- UZQFDHKWLNUAHL-FRAXYZTQSA-N (3s)-3-[[5-(1h-imidazol-2-ylmethyl)-3-[(1s)-2-methyl-1-(quinoline-2-carbonylamino)propyl]-4h-1,2-oxazole-5-carbonyl]amino]-4-oxo-5-phenoxypentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2N=C3C=CC=CC3=CC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)COC=1C=CC=CC=1)CC1=NC=CN1 UZQFDHKWLNUAHL-FRAXYZTQSA-N 0.000 claims description 2
- KKWSENWDEWIJOL-YXBGZAQISA-N (3s)-3-[[5-benzyl-3-[(1s)-1-(isoquinoline-1-carbonylamino)-2-methylpropyl]-4h-1,2-oxazole-5-carbonyl]amino]-5-(2,6-dichlorobenzoyl)oxy-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2C3=CC=CC=C3C=CN=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)CC1=CC=CC=C1 KKWSENWDEWIJOL-YXBGZAQISA-N 0.000 claims description 2
- AKXQAZGFKWMLQL-SJVPFVBJSA-N (3s)-3-[[5-benzyl-3-[(1s)-1-[[2-(1h-indol-3-yl)acetyl]amino]-2-methylpropyl]-4h-1,2-oxazole-5-carbonyl]amino]-5-(2,6-dichlorobenzoyl)oxy-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)CC=2C3=CC=CC=C3NC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)CC1=CC=CC=C1 AKXQAZGFKWMLQL-SJVPFVBJSA-N 0.000 claims description 2
- FSCBFBMBTAUVPR-VMZLPSRASA-N (3s)-3-[[5-benzyl-3-[(1s)-1-[[2-(1h-indol-3-yl)acetyl]amino]-2-methylpropyl]-4h-1,2-oxazole-5-carbonyl]amino]-5-bromo-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)CC=2C3=CC=CC=C3NC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)CBr)CC1=CC=CC=C1 FSCBFBMBTAUVPR-VMZLPSRASA-N 0.000 claims description 2
- MAXNYXFKLCHDCT-HVZFRMHZSA-N (3s)-3-[[5-benzyl-3-[(1s)-2-methyl-1-(3-phenylpropanoylamino)propyl]-4h-1,2-oxazole-5-carbonyl]amino]-5-(2,6-dichlorobenzoyl)oxy-4-oxopentanoic acid Chemical compound N([C@@H](C(C)C)C=1CC(CC=2C=CC=CC=2)(ON=1)C(=O)N[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)C(=O)CCC1=CC=CC=C1 MAXNYXFKLCHDCT-HVZFRMHZSA-N 0.000 claims description 2
- UOMFFTQTZBTJLF-UCWKTWOXSA-N (3s)-3-[[5-benzyl-3-[(1s)-2-methyl-1-(3-phenylpropanoylamino)propyl]-4h-1,2-oxazole-5-carbonyl]amino]-5-bromo-4-oxopentanoic acid Chemical compound N([C@@H](C(C)C)C=1CC(CC=2C=CC=CC=2)(ON=1)C(=O)N[C@@H](CC(O)=O)C(=O)CBr)C(=O)CCC1=CC=CC=C1 UOMFFTQTZBTJLF-UCWKTWOXSA-N 0.000 claims description 2
- DMRUMEWSIDADTO-XBUSXREVSA-N (3s)-3-[[5-benzyl-3-[(1s)-2-methyl-1-(naphthalene-1-carbonylamino)propyl]-4h-1,2-oxazole-5-carbonyl]amino]-5-(2,6-dimethylbenzoyl)oxy-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2C3=CC=CC=C3C=CC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1C)C)CC1=CC=CC=C1 DMRUMEWSIDADTO-XBUSXREVSA-N 0.000 claims description 2
- NCXNIBNVHVEPEZ-MBLJMWHHSA-N (3s)-3-[[5-benzyl-3-[(1s)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-4h-1,2-oxazole-5-carbonyl]amino]-5-(2,6-dichlorobenzoyl)oxy-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2C=C3C=CC=CC3=CC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)CC1=CC=CC=C1 NCXNIBNVHVEPEZ-MBLJMWHHSA-N 0.000 claims description 2
- AENHVHNUHDDEQX-RYZOHKRZSA-N (3s)-3-[[5-benzyl-3-[(1s)-2-methyl-1-(phenylmethoxycarbonylamino)propyl]-4h-1,2-oxazole-5-carbonyl]amino]-5-(2,6-dichlorobenzoyl)oxy-4-oxopentanoic acid Chemical compound N([C@@H](C(C)C)C=1CC(CC=2C=CC=CC=2)(ON=1)C(=O)N[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)C(=O)OCC1=CC=CC=C1 AENHVHNUHDDEQX-RYZOHKRZSA-N 0.000 claims description 2
- YNYCQNGEVBGHPK-LDQYRDBOSA-N (3s)-5-(2,6-dichlorobenzoyl)oxy-3-[methyl-[3-[(1s)-2-methyl-1-(naphthalen-1-ylsulfonylamino)propyl]-5-phenyl-4h-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound O=C([C@H](CC(O)=O)N(C)C(=O)C1(ON=C(C1)[C@@H](NS(=O)(=O)C=1C2=CC=CC=C2C=CC=1)C(C)C)C=1C=CC=CC=1)COC(=O)C1=C(Cl)C=CC=C1Cl YNYCQNGEVBGHPK-LDQYRDBOSA-N 0.000 claims description 2
- GBCHWHCSEQVCDI-PJXAABHXSA-N (3s)-5-(2,6-dichlorobenzoyl)oxy-3-[methyl-[3-[(1s)-2-methyl-1-(naphthalene-1-carbonylamino)propyl]-5-phenyl-4h-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound O=C([C@H](CC(O)=O)N(C)C(=O)C1(ON=C(C1)[C@@H](NC(=O)C=1C2=CC=CC=C2C=CC=1)C(C)C)C=1C=CC=CC=1)COC(=O)C1=C(Cl)C=CC=C1Cl GBCHWHCSEQVCDI-PJXAABHXSA-N 0.000 claims description 2
- HTIGGFKCBPGERF-YOGAAICWSA-N (3s)-5-(2,6-dichlorobenzoyl)oxy-3-[methyl-[3-[(1s)-2-methyl-1-(quinoline-3-carbonylamino)propyl]-5-phenyl-4h-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound O=C([C@H](CC(O)=O)N(C)C(=O)C1(ON=C(C1)[C@@H](NC(=O)C=1C=C2C=CC=CC2=NC=1)C(C)C)C=1C=CC=CC=1)COC(=O)C1=C(Cl)C=CC=C1Cl HTIGGFKCBPGERF-YOGAAICWSA-N 0.000 claims description 2
- LGRSQXAPKHNRSC-PJXAABHXSA-N (3s)-5-(2,6-difluorobenzoyl)oxy-3-[methyl-[3-[(1s)-2-methyl-1-(naphthalene-1-carbonylamino)propyl]-5-phenyl-4h-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound O=C([C@H](CC(O)=O)N(C)C(=O)C1(ON=C(C1)[C@@H](NC(=O)C=1C2=CC=CC=C2C=CC=1)C(C)C)C=1C=CC=CC=1)COC(=O)C1=C(F)C=CC=C1F LGRSQXAPKHNRSC-PJXAABHXSA-N 0.000 claims description 2
- NCPXZELTLIWUGP-OZIHFDBSSA-N (3s)-5-bromo-3-[[3-[(1s)-2-methyl-1-(phenylmethoxycarbonylamino)propyl]-4,5-dihydro-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound N([C@@H](C(C)C)C=1CC(ON=1)C(=O)N[C@@H](CC(O)=O)C(=O)CBr)C(=O)OCC1=CC=CC=C1 NCPXZELTLIWUGP-OZIHFDBSSA-N 0.000 claims description 2
- BIHVRXMWAXQILG-NUOXSBERSA-N (3s)-5-bromo-3-[[3-[(1s)-2-methyl-1-(quinoline-2-carbonylamino)propyl]-4,5-dihydro-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound C1([C@@H](NC(=O)C=2N=C3C=CC=CC3=CC=2)C(C)C)=NOC(C(=O)N[C@@H](CC(O)=O)C(=O)CBr)C1 BIHVRXMWAXQILG-NUOXSBERSA-N 0.000 claims description 2
- APOFXDORVYWIDR-MJLQIQFDSA-N (3s)-5-bromo-3-[methyl-[3-[(1s)-2-methyl-1-(naphthalen-1-ylsulfonylamino)propyl]-5-phenyl-4h-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound C1C([C@@H](NS(=O)(=O)C=2C3=CC=CC=C3C=CC=2)C(C)C)=NOC1(C(=O)N(C)[C@@H](CC(O)=O)C(=O)CBr)C1=CC=CC=C1 APOFXDORVYWIDR-MJLQIQFDSA-N 0.000 claims description 2
- FCZSZTADVCWDFD-HXVHBBJOSA-N (3s)-5-bromo-3-[methyl-[3-[(1s)-2-methyl-1-(quinoline-2-carbonylamino)propyl]-5-phenyl-4h-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2N=C3C=CC=CC3=CC=2)C(C)C)=NOC1(C(=O)N(C)[C@@H](CC(O)=O)C(=O)CBr)C1=CC=CC=C1 FCZSZTADVCWDFD-HXVHBBJOSA-N 0.000 claims description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims description 2
- 101150065749 Churc1 gene Proteins 0.000 claims description 2
- FDDXKSCVLAZNKO-UHFFFAOYSA-N ClC1=C(C(=O)OC(C(=O)O)CCC)C(=CC=C1)Cl Chemical compound ClC1=C(C(=O)OC(C(=O)O)CCC)C(=CC=C1)Cl FDDXKSCVLAZNKO-UHFFFAOYSA-N 0.000 claims description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 2
- 102100038239 Protein Churchill Human genes 0.000 claims description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 claims description 2
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 claims description 2
- 230000006735 deficit Effects 0.000 claims description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 2
- 210000002064 heart cell Anatomy 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 2
- 125000005647 linker group Chemical group 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 claims description 2
- 125000004742 propyloxycarbonyl group Chemical group 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 claims description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 2
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 claims description 2
- 150000003536 tetrazoles Chemical class 0.000 claims description 2
- 150000003852 triazoles Chemical class 0.000 claims description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 150000001805 chlorine compounds Chemical class 0.000 claims 2
- CAFXLBCDFMSQEF-OZEVUELHSA-N (2s)-2-[[3-[(1s)-2-methyl-1-(phenylmethoxycarbonylamino)propyl]-5-(phenoxymethyl)-4h-1,2-oxazole-5-carbonyl]amino]butanedioic acid Chemical compound N([C@@H](C(C)C)C=1CC(COC=2C=CC=CC=2)(ON=1)C(=O)N[C@@H](CC(O)=O)C(O)=O)C(=O)OCC1=CC=CC=C1 CAFXLBCDFMSQEF-OZEVUELHSA-N 0.000 claims 1
- ITBRCUIUJRCQTA-LUIVKCTASA-N (3S)-3-[[5-benzyl-3-[(1S)-1-[3-(1H-indol-3-yl)propanoylamino]-2-methylpropyl]-4H-1,2-oxazole-5-carbonyl]amino]-5-diazo-4-oxopentanoic acid Chemical compound CC([C@H](NC(=O)CCC1=CNC2=CC=CC=C12)C1=NOC(C1)(C(=O)N[C@@H](CC(=O)O)C(C=[N+]=[N-])=O)CC1=CC=CC=C1)C ITBRCUIUJRCQTA-LUIVKCTASA-N 0.000 claims 1
- DUODEWFZJZFKEH-UCWKTWOXSA-N (3S)-3-[[5-benzyl-3-[(1S)-2-methyl-1-(3-phenylpropanoylamino)propyl]-4H-1,2-oxazole-5-carbonyl]amino]-5-diazo-4-oxopentanoic acid Chemical compound N([C@@H](C(C)C)C=1CC(CC=2C=CC=CC=2)(ON=1)C(=O)N[C@@H](CC(O)=O)C(=O)C=[N+]=[N-])C(=O)CCC1=CC=CC=C1 DUODEWFZJZFKEH-UCWKTWOXSA-N 0.000 claims 1
- PBHKVNKFBJHGFW-YTCSIFFLSA-N (3S)-3-[[5-benzyl-3-[(1S)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-4H-1,2-oxazole-5-carbonyl]amino]-5-diazo-4-oxopentanoic acid Chemical compound C1=C(C=CC2=CC=CC=C12)C(=O)N[C@@H](C(C)C)C1=NOC(C1)(C(=O)N[C@@H](CC(=O)O)C(C=[N+]=[N-])=O)CC1=CC=CC=C1 PBHKVNKFBJHGFW-YTCSIFFLSA-N 0.000 claims 1
- PXNNLAVUDDZVNO-YTCSIFFLSA-N (3S)-5-diazo-3-[[3-[(1S)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-5-(phenoxymethyl)-4H-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2C=C3C=CC=CC3=CC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)C=[N+]=[N-])COC1=CC=CC=C1 PXNNLAVUDDZVNO-YTCSIFFLSA-N 0.000 claims 1
- BGIGRGQZRXKGKP-HXVHBBJOSA-N (3S)-5-diazo-3-[methyl-[3-[(1S)-2-methyl-1-(quinoline-2-carbonylamino)propyl]-5-phenyl-4H-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound CC(C)[C@H](NC(=O)c1ccc2ccccc2n1)C1=NOC(C1)(C(=O)N(C)[C@@H](CC(O)=O)C(=O)C=[N+]=[N-])c1ccccc1 BGIGRGQZRXKGKP-HXVHBBJOSA-N 0.000 claims 1
- GTRROSGIPGOFSD-BYNDPHFLSA-N (3s)-3-[[3-[(1s)-2-methyl-1-(naphthalen-2-ylsulfonylamino)propyl]-5-(phenoxymethyl)-4h-1,2-oxazole-5-carbonyl]amino]-4-oxo-5-phenoxypentanoic acid Chemical compound C1C([C@@H](NS(=O)(=O)C=2C=C3C=CC=CC3=CC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)COC=1C=CC=CC=1)COC1=CC=CC=C1 GTRROSGIPGOFSD-BYNDPHFLSA-N 0.000 claims 1
- NLPCZOFSBWFMCG-YJAGCLLGSA-N (3s)-3-[[5-benzyl-3-[(1s)-1-(isoquinoline-3-carbonylamino)-2-methylpropyl]-4h-1,2-oxazole-5-carbonyl]amino]-5-(2,6-dichlorobenzoyl)oxy-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2N=CC3=CC=CC=C3C=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)CC1=CC=CC=C1 NLPCZOFSBWFMCG-YJAGCLLGSA-N 0.000 claims 1
- WIZIFQIBWIXRLJ-RQQCDAHVSA-N (3s)-3-[[5-benzyl-3-[(1s)-1-[3-(1h-indol-3-yl)propanoylamino]-2-methylpropyl]-4h-1,2-oxazole-5-carbonyl]amino]-5-(2,6-dichlorobenzoyl)oxy-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)CCC=2C3=CC=CC=C3NC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)CC1=CC=CC=C1 WIZIFQIBWIXRLJ-RQQCDAHVSA-N 0.000 claims 1
- DWVVQZGYFKBAGG-LUIVKCTASA-N (3s)-3-[[5-benzyl-3-[(1s)-1-[3-(1h-indol-3-yl)propanoylamino]-2-methylpropyl]-4h-1,2-oxazole-5-carbonyl]amino]-5-bromo-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)CCC=2C3=CC=CC=C3NC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)CBr)CC1=CC=CC=C1 DWVVQZGYFKBAGG-LUIVKCTASA-N 0.000 claims 1
- AMYPFDACYDDCLQ-GENHCFSWSA-N (3s)-3-[[5-benzyl-3-[(1s)-2-methyl-1-(naphthalene-1-carbonylamino)propyl]-4h-1,2-oxazole-5-carbonyl]amino]-4-oxo-5-piperidin-1-ylpentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2C3=CC=CC=C3C=CC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)CN1CCCCC1)CC1=CC=CC=C1 AMYPFDACYDDCLQ-GENHCFSWSA-N 0.000 claims 1
- QICDVZBKNAIKBT-YTCSIFFLSA-N (3s)-3-[[5-benzyl-3-[(1s)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-4h-1,2-oxazole-5-carbonyl]amino]-5-bromo-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2C=C3C=CC=CC3=CC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)CBr)CC1=CC=CC=C1 QICDVZBKNAIKBT-YTCSIFFLSA-N 0.000 claims 1
- IBXAGCABLPLNPJ-XSSWLBODSA-N (3s)-3-[[5-benzyl-3-[(1s)-2-methyl-1-(phenylmethoxycarbonylamino)propyl]-4h-1,2-oxazole-5-carbonyl]amino]-5-bromo-4-oxopentanoic acid Chemical compound N([C@@H](C(C)C)C=1CC(CC=2C=CC=CC=2)(ON=1)C(=O)N[C@@H](CC(O)=O)C(=O)CBr)C(=O)OCC1=CC=CC=C1 IBXAGCABLPLNPJ-XSSWLBODSA-N 0.000 claims 1
- MSLBNHPUNPIBKM-HSFHSNDNSA-N (3s)-3-[methyl-[3-[(1s)-2-methyl-1-(quinoline-2-carbonylamino)propyl]-5-phenyl-4h-1,2-oxazole-5-carbonyl]amino]-4-oxo-5-phenoxypentanoic acid Chemical compound O=C([C@H](CC(O)=O)N(C)C(=O)C1(ON=C(C1)[C@@H](NC(=O)C=1N=C2C=CC=CC2=CC=1)C(C)C)C=1C=CC=CC=1)COC1=CC=CC=C1 MSLBNHPUNPIBKM-HSFHSNDNSA-N 0.000 claims 1
- XVHCLVAUKBWUNQ-MBLJMWHHSA-N (3s)-5-(2,6-dichlorobenzoyl)oxy-3-[[3-[(1s)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-5-(phenoxymethyl)-4h-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2C=C3C=CC=CC3=CC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)COC1=CC=CC=C1 XVHCLVAUKBWUNQ-MBLJMWHHSA-N 0.000 claims 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- 125000005979 2-naphthyloxy group Chemical group 0.000 claims 1
- GSSXLFACIJSBOM-UHFFFAOYSA-N 2h-pyran-2-ol Chemical compound OC1OC=CC=C1 GSSXLFACIJSBOM-UHFFFAOYSA-N 0.000 claims 1
- 208000022306 Cerebral injury Diseases 0.000 claims 1
- 150000001491 aromatic compounds Chemical class 0.000 claims 1
- 125000004212 difluorophenyl group Chemical group 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- SJKZGWVTHFTCJY-RUFIAJSPSA-N methyl (3s)-3-[[3-[(1s)-2-methyl-1-(phenylmethoxycarbonylamino)propyl]-4,5-dihydro-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoate Chemical compound O1C(C(=O)N[C@@H](CC(=O)OC)C(C)=O)CC([C@@H](NC(=O)OCC=2C=CC=CC=2)C(C)C)=N1 SJKZGWVTHFTCJY-RUFIAJSPSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 56
- 230000002401 inhibitory effect Effects 0.000 abstract description 25
- 208000006011 Stroke Diseases 0.000 abstract description 5
- 230000002440 hepatic effect Effects 0.000 abstract description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 192
- 238000005160 1H NMR spectroscopy Methods 0.000 description 174
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 74
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 64
- 239000011734 sodium Substances 0.000 description 49
- 125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 44
- 210000003494 hepatocyte Anatomy 0.000 description 42
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 41
- 102100040247 Tumor necrosis factor Human genes 0.000 description 40
- 239000000243 solution Substances 0.000 description 39
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 37
- 230000015572 biosynthetic process Effects 0.000 description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 35
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 34
- 238000003786 synthesis reaction Methods 0.000 description 34
- 229940126639 Compound 33 Drugs 0.000 description 32
- 210000004185 liver Anatomy 0.000 description 26
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 26
- 108010062580 Concanavalin A Proteins 0.000 description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 19
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 229940088598 enzyme Drugs 0.000 description 16
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 15
- 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- 206010067125 Liver injury Diseases 0.000 description 12
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 12
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 12
- 230000001640 apoptogenic effect Effects 0.000 description 12
- 235000019439 ethyl acetate Nutrition 0.000 description 12
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 12
- 238000003818 flash chromatography Methods 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 12
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 11
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 11
- 108090000397 Caspase 3 Proteins 0.000 description 11
- 102100029855 Caspase-3 Human genes 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 11
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 11
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 10
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 231100000673 dose–response relationship Toxicity 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000003833 cell viability Effects 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 9
- 231100000234 hepatic damage Toxicity 0.000 description 9
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 9
- 230000008818 liver damage Effects 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 102100035904 Caspase-1 Human genes 0.000 description 8
- 108090000426 Caspase-1 Proteins 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000010626 work up procedure Methods 0.000 description 8
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 7
- 108010092160 Dactinomycin Proteins 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 210000005229 liver cell Anatomy 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 6
- 102000004091 Caspase-8 Human genes 0.000 description 6
- 108090000538 Caspase-8 Proteins 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 229960000640 dactinomycin Drugs 0.000 description 6
- 238000011835 investigation Methods 0.000 description 6
- 208000019423 liver disease Diseases 0.000 description 6
- 210000005228 liver tissue Anatomy 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 150000002923 oximes Chemical class 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- GGXRLUDNGFFUKI-ORGXJRBJSA-N (4s)-4-[[(2s)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2s)-1-[[(2s)-3-carboxy-1-(4-nitroanilino)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)C[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 GGXRLUDNGFFUKI-ORGXJRBJSA-N 0.000 description 5
- 102000004018 Caspase 6 Human genes 0.000 description 5
- 108090000425 Caspase 6 Proteins 0.000 description 5
- 108090000567 Caspase 7 Proteins 0.000 description 5
- 102100038902 Caspase-7 Human genes 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 108010038407 acetyl-aspartyl-glutamyl-valyl-aspartic acid p-nitroanilide Proteins 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- WJYKTKYUYUAMNU-SIPNUGOWSA-N (3s)-3-[[3-[(1s)-1-(1-benzofuran-2-carbonylamino)-2-methylpropyl]-5-methyl-4h-1,2-oxazole-5-carbonyl]amino]-5-(2,6-dichlorobenzoyl)oxy-4-oxopentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)C1(C)ON=C(C1)[C@@H](NC(=O)C=1OC2=CC=CC=C2C=1)C(C)C)COC(=O)C1=C(Cl)C=CC=C1Cl WJYKTKYUYUAMNU-SIPNUGOWSA-N 0.000 description 4
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 4
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 4
- UMBVAPCONCILTL-MRHIQRDNSA-N Ac-Asp-Glu-Val-Asp-H Chemical compound OC(=O)C[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(C)=O UMBVAPCONCILTL-MRHIQRDNSA-N 0.000 description 4
- 102000004046 Caspase-2 Human genes 0.000 description 4
- 108090000552 Caspase-2 Proteins 0.000 description 4
- 102100025597 Caspase-4 Human genes 0.000 description 4
- 101710090338 Caspase-4 Proteins 0.000 description 4
- 102000004039 Caspase-9 Human genes 0.000 description 4
- 108090000566 Caspase-9 Proteins 0.000 description 4
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 4
- 206010019663 Hepatic failure Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 108010066665 acetyl-aspartyl-glutamyl-valyl-aspartal Proteins 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- AOJDZKCUAATBGE-UHFFFAOYSA-N bromomethane Chemical compound Br[CH2] AOJDZKCUAATBGE-UHFFFAOYSA-N 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000001952 enzyme assay Methods 0.000 description 4
- 238000013467 fragmentation Methods 0.000 description 4
- 238000006062 fragmentation reaction Methods 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 208000007903 liver failure Diseases 0.000 description 4
- 231100000835 liver failure Toxicity 0.000 description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 3
- 102100038023 DNA fragmentation factor subunit beta Human genes 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 108010042238 caspase-activated deoxyribonuclease Proteins 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000003235 crystal violet staining Methods 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 231100000304 hepatotoxicity Toxicity 0.000 description 3
- 230000036732 histological change Effects 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 230000007056 liver toxicity Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 150000004702 methyl esters Chemical class 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000001384 succinic acid Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- GDEFTSVRKIMSSK-UEWDXFNNSA-N tert-butyl (3s)-3-amino-4-hydroxy-5-phenoxypentanoate Chemical compound CC(C)(C)OC(=O)C[C@H](N)C(O)COC1=CC=CC=C1 GDEFTSVRKIMSSK-UEWDXFNNSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- INILVVRYUSAMIQ-KIYNQFGBSA-N (3s)-2-tert-butyl-3-(phenylmethoxycarbonylamino)butanedioic acid Chemical compound CC(C)(C)C(C(O)=O)[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 INILVVRYUSAMIQ-KIYNQFGBSA-N 0.000 description 2
- YDPNOCSPPGFBPX-XNHCRPTKSA-N (3s)-3-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-(4-nitroanilino)-4-oxobutanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)NC(C)=O)C1=CC=C(O)C=C1 YDPNOCSPPGFBPX-XNHCRPTKSA-N 0.000 description 2
- CJGIRZPJDLPHCF-IHBUOKDLSA-N (3s)-3-[[3-[(1s)-1-(1-benzofuran-2-carbonylamino)-2-methylpropyl]-5-benzyl-4h-1,2-oxazole-5-carbonyl]amino]-5-(2,6-dichlorobenzoyl)oxy-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2OC3=CC=CC=C3C=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)CC1=CC=CC=C1 CJGIRZPJDLPHCF-IHBUOKDLSA-N 0.000 description 2
- QRRKWRLYGWPGMS-SUNKFUHCSA-N (3s)-3-[[5-benzyl-3-[(1s)-1-(isoquinoline-4-carbonylamino)-2-methylpropyl]-4h-1,2-oxazole-5-carbonyl]amino]-5-(2,6-dichlorobenzoyl)oxy-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2C3=CC=CC=C3C=NC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)CC1=CC=CC=C1 QRRKWRLYGWPGMS-SUNKFUHCSA-N 0.000 description 2
- GNOBSSWWPSHUIM-MBLJMWHHSA-N (3s)-3-[[5-benzyl-3-[(1s)-2-methyl-1-(naphthalene-1-carbonylamino)propyl]-4h-1,2-oxazole-5-carbonyl]amino]-5-(2,6-difluorobenzoyl)oxy-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2C3=CC=CC=C3C=CC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1F)F)CC1=CC=CC=C1 GNOBSSWWPSHUIM-MBLJMWHHSA-N 0.000 description 2
- LQQKDSXCDXHLLF-UHFFFAOYSA-N 1,3-dibromopropan-2-one Chemical class BrCC(=O)CBr LQQKDSXCDXHLLF-UHFFFAOYSA-N 0.000 description 2
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 2
- FGOJCPKOOGIRPA-UHFFFAOYSA-N 1-o-tert-butyl 4-o-ethyl 5-oxoazepane-1,4-dicarboxylate Chemical compound CCOC(=O)C1CCN(C(=O)OC(C)(C)C)CCC1=O FGOJCPKOOGIRPA-UHFFFAOYSA-N 0.000 description 2
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 2
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 108010008106 acetyl-tyrosyl-valyl-alanyl-aspartic acid p-nitroanilide Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 150000001509 aspartic acid derivatives Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- NQIOYIIIDJVRSG-NSHDSACASA-N benzyl n-[(2s)-1-chloro-1-hydroxyimino-3-methylbutan-2-yl]carbamate Chemical compound ON=C(Cl)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 NQIOYIIIDJVRSG-NSHDSACASA-N 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229940126545 compound 53 Drugs 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- XXTZHYXQVWRADW-UHFFFAOYSA-N diazomethanone Chemical compound [N]N=C=O XXTZHYXQVWRADW-UHFFFAOYSA-N 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- ROORDVPLFPIABK-UHFFFAOYSA-N diphenyl carbonate Chemical compound C=1C=CC=CC=1OC(=O)OC1=CC=CC=C1 ROORDVPLFPIABK-UHFFFAOYSA-N 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- MTCMFVTVXAOHNQ-UHFFFAOYSA-N ethyl 2-(bromomethyl)prop-2-enoate Chemical compound CCOC(=O)C(=C)CBr MTCMFVTVXAOHNQ-UHFFFAOYSA-N 0.000 description 2
- OCTNSVPQFFDELX-UHFFFAOYSA-N ethyl 2-(phenoxymethyl)prop-2-enoate Chemical compound CCOC(=O)C(=C)COC1=CC=CC=C1 OCTNSVPQFFDELX-UHFFFAOYSA-N 0.000 description 2
- GBXWOOXBPQDZED-FUKCDUGKSA-N ethyl 5-butyl-3-[(1s)-2-methyl-1-[(2-methylpropan-2-yl)oxycarbonylamino]propyl]-4h-1,2-oxazole-5-carboxylate Chemical compound CCCCC1(C(=O)OCC)CC([C@@H](NC(=O)OC(C)(C)C)C(C)C)=NO1 GBXWOOXBPQDZED-FUKCDUGKSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000028974 hepatocyte apoptotic process Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000003901 oxalic acid esters Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- SWWYEKADAPOQDA-OJBLAGBYSA-N (2s)-2-[[5-benzyl-3-[(1s)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-4h-1,2-oxazole-5-carbonyl]amino]-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1C([C@@H](NC(=O)C=2C=C3C=CC=CC3=CC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)CC1=CC=CC=C1 SWWYEKADAPOQDA-OJBLAGBYSA-N 0.000 description 1
- DVOFEOSDXAVUJD-RXMQYKEDSA-N (2s)-2-amino-3-methylbutanal Chemical compound CC(C)[C@H](N)C=O DVOFEOSDXAVUJD-RXMQYKEDSA-N 0.000 description 1
- WDIMHUVQORAJAB-AKGZTFGVSA-N (2s)-2-amino-3-tert-butylbutanedioic acid Chemical compound CC(C)(C)C(C(O)=O)[C@H](N)C(O)=O WDIMHUVQORAJAB-AKGZTFGVSA-N 0.000 description 1
- RELDFRMPWHGLLM-XSSWLBODSA-N (3S)-3-[[5-benzyl-3-[(1S)-2-methyl-1-(phenylmethoxycarbonylamino)propyl]-4H-1,2-oxazole-5-carbonyl]amino]-5-diazo-4-oxopentanoic acid Chemical compound N([C@@H](C(C)C)C=1CC(CC=2C=CC=CC=2)(ON=1)C(=O)N[C@@H](CC(O)=O)C(=O)C=[N+]=[N-])C(=O)OCC1=CC=CC=C1 RELDFRMPWHGLLM-XSSWLBODSA-N 0.000 description 1
- GQLIIMJKTVIQDZ-WVLLBIQGSA-N (3S)-3-[methyl-[3-[(1S)-2-methyl-1-(naphthalen-2-ylsulfonylamino)propyl]-5-phenoxy-4H-1,2-oxazole-5-carbonyl]amino]-4-oxo-5-phenoxypentanoic acid Chemical compound C1=C(C=CC2=CC=CC=C12)S(=O)(=O)N[C@@H](C(C)C)C1=NOC(C1)(C(=O)N([C@@H](CC(=O)O)C(COC1=CC=CC=C1)=O)C)OC1=CC=CC=C1 GQLIIMJKTVIQDZ-WVLLBIQGSA-N 0.000 description 1
- IDSSUOKXTIHRGT-SNXXJJMMSA-N (3S)-3-[methyl-[3-[(1S)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-5-phenoxy-4H-1,2-oxazole-5-carbonyl]amino]-5-naphthalen-1-yloxy-4-oxopentanoic acid Chemical compound C1=C(C=CC2=CC=CC=C12)C(=O)N[C@@H](C(C)C)C1=NOC(C1)(C(=O)N([C@@H](CC(=O)O)C(COC1=CC=CC2=CC=CC=C12)=O)C)OC1=CC=CC=C1 IDSSUOKXTIHRGT-SNXXJJMMSA-N 0.000 description 1
- URCPIFXUJIAFPO-YOGAAICWSA-N (3S)-5-(2,6-dichlorobenzoyl)oxy-3-[[3-[(1S)-1-(isoquinoline-3-carbonylamino)-2-methylpropyl]-5-phenyl-4H-1,2-oxazole-5-carbonyl]-methylamino]-4-oxopentanoic acid Chemical compound CC(C)[C@H](NC(=O)c1cc2ccccc2cn1)C1=NOC(C1)(C(=O)N(C)[C@@H](CC(O)=O)C(=O)COC(=O)c1c(Cl)cccc1Cl)c1ccccc1 URCPIFXUJIAFPO-YOGAAICWSA-N 0.000 description 1
- FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 1
- XOQBEABUTUIXHL-RXKSKBTASA-N (3S)-5-bromo-3-[methyl-[3-[(1S)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-5-phenoxy-4H-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound C1=C(C=CC2=CC=CC=C12)C(=O)N[C@@H](C(C)C)C1=NOC(C1)(C(=O)N([C@@H](CC(=O)O)C(CBr)=O)C)OC1=CC=CC=C1 XOQBEABUTUIXHL-RXKSKBTASA-N 0.000 description 1
- NSEBUYIBQYXRHE-JFCBHCIBSA-N (3S)-5-diazo-3-[methyl-[3-[(1S)-2-methyl-1-(3-phenylpropanoylamino)propyl]-5-phenyl-4H-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound CC([C@H](NC(=O)CCC1=CC=CC=C1)C1=NOC(C1)(C(=O)N([C@@H](CC(=O)O)C(C=[N+]=[N-])=O)C)C1=CC=CC=C1)C NSEBUYIBQYXRHE-JFCBHCIBSA-N 0.000 description 1
- XXZLTWJRSDEOBQ-RXKSKBTASA-N (3S)-5-diazo-3-[methyl-[3-[(1S)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-5-phenoxy-4H-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound C1=C(C=CC2=CC=CC=C12)C(=O)N[C@@H](C(C)C)C1=NOC(C1)(C(=O)N([C@@H](CC(=O)O)C(C=[N+]=[N-])=O)C)OC1=CC=CC=C1 XXZLTWJRSDEOBQ-RXKSKBTASA-N 0.000 description 1
- MBZFNGSPLHMROM-RXKSKBTASA-N (3S)-5-diazo-3-[methyl-[3-[(1S)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-5-phenyl-4H-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound C1=C(C=CC2=CC=CC=C12)C(=O)N[C@@H](C(C)C)C1=NOC(C1)(C(=O)N([C@@H](CC(=O)O)C(C=[N+]=[N-])=O)C)C1=CC=CC=C1 MBZFNGSPLHMROM-RXKSKBTASA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- SCFIGTCUOODJIJ-XOQPTCEHSA-N (3s)-3-[[3-[(1s)-2-methyl-1-(naphthalene-1-carbonylamino)propyl]-5-(phenoxymethyl)-4h-1,2-oxazole-5-carbonyl]amino]-4-oxo-5-phenoxypentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2C3=CC=CC=C3C=CC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)COC=1C=CC=CC=1)COC1=CC=CC=C1 SCFIGTCUOODJIJ-XOQPTCEHSA-N 0.000 description 1
- WIEWPGDCGMZZKI-HGAQVFRKSA-N (3s)-3-[[3-[(1s)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-4,5-dihydro-1,2-oxazole-5-carbonyl]amino]-4-oxo-5-phenoxypentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)C1ON=C(C1)[C@@H](NC(=O)C=1C=C2C=CC=CC2=CC=1)C(C)C)COC1=CC=CC=C1 WIEWPGDCGMZZKI-HGAQVFRKSA-N 0.000 description 1
- BEYPDRJSGSEUJE-KHLAINANSA-N (3s)-3-[[3-[(1s)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-4,5-dihydro-1,2-oxazole-5-carbonyl]amino]-5-naphthalen-2-yloxy-4-oxopentanoic acid Chemical compound C1=CC=CC2=CC(OCC(=O)[C@H](CC(O)=O)NC(=O)C3ON=C(C3)[C@@H](NC(=O)C=3C=C4C=CC=CC4=CC=3)C(C)C)=CC=C21 BEYPDRJSGSEUJE-KHLAINANSA-N 0.000 description 1
- YLMQVFRZXUHKMS-MKYWAZEISA-N (3s)-3-[[5-benzyl-3-[(1s)-1-(benzylsulfonylamino)-2-methylpropyl]-4h-1,2-oxazole-5-carbonyl]amino]-5-(2,6-dichlorobenzoyl)oxy-4-oxopentanoic acid Chemical compound N([C@@H](C(C)C)C=1CC(CC=2C=CC=CC=2)(ON=1)C(=O)N[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)S(=O)(=O)CC1=CC=CC=C1 YLMQVFRZXUHKMS-MKYWAZEISA-N 0.000 description 1
- UMGPCOCVBJTMPN-RXKSKBTASA-N (3s)-3-[[5-benzyl-3-[(1s)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-4h-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2C=C3C=CC=CC3=CC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(C)=O)CC1=CC=CC=C1 UMGPCOCVBJTMPN-RXKSKBTASA-N 0.000 description 1
- DZCSLMZJHCSZIW-GENHCFSWSA-N (3s)-3-[[5-benzyl-3-[(1s)-2-methyl-1-(quinoline-2-carbonylamino)propyl]-4h-1,2-oxazole-5-carbonyl]amino]-4-oxo-5-phenoxypentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2N=C3C=CC=CC3=CC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)COC=1C=CC=CC=1)CC1=CC=CC=C1 DZCSLMZJHCSZIW-GENHCFSWSA-N 0.000 description 1
- LXBJVXZEEASILR-HSFHSNDNSA-N (3s)-3-[methyl-[3-[(1s)-2-methyl-1-(naphthalene-1-carbonylamino)propyl]-5-phenyl-4h-1,2-oxazole-5-carbonyl]amino]-4-oxo-5-piperidin-1-ylpentanoic acid Chemical compound O=C([C@H](CC(O)=O)N(C)C(=O)C1(ON=C(C1)[C@@H](NC(=O)C=1C2=CC=CC=C2C=CC=1)C(C)C)C=1C=CC=CC=1)CN1CCCCC1 LXBJVXZEEASILR-HSFHSNDNSA-N 0.000 description 1
- VOZCEJIQXRKBMM-PFNNSMBTSA-N (3s)-3-[methyl-[3-[(1s)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-5-phenoxy-4h-1,2-oxazole-5-carbonyl]amino]-4-oxo-5-phenoxypentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2C=C3C=CC=CC3=CC=2)C(C)C)=NOC1(C(=O)N(C)[C@@H](CC(O)=O)C(=O)COC=1C=CC=CC=1)OC1=CC=CC=C1 VOZCEJIQXRKBMM-PFNNSMBTSA-N 0.000 description 1
- NFFMSOKTSYAIPY-OZEXRGSVSA-N (3s)-3-[methyl-[3-[(1s)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-5-phenoxy-4h-1,2-oxazole-5-carbonyl]amino]-5-naphthalen-2-yloxy-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2C=C3C=CC=CC3=CC=2)C(C)C)=NOC1(C(=O)N(C)[C@@H](CC(O)=O)C(=O)COC=1C=C2C=CC=CC2=CC=1)OC1=CC=CC=C1 NFFMSOKTSYAIPY-OZEXRGSVSA-N 0.000 description 1
- LHGFBSCCFLMSAO-FJQNPZFOSA-N (3s)-3-[methyl-[3-[(1s)-2-methyl-1-(quinoline-2-carbonylamino)propyl]-5-phenoxy-4h-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2N=C3C=CC=CC3=CC=2)C(C)C)=NOC1(C(=O)N(C)[C@@H](CC(O)=O)C(C)=O)OC1=CC=CC=C1 LHGFBSCCFLMSAO-FJQNPZFOSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- KVKFNHACKSHMOT-FJCNXOJISA-N (3s)-5-(2,6-dichlorobenzoyl)oxy-3-[[3-[(1s)-1-(isoquinoline-1-carbonylamino)-2-methylpropyl]-5-phenyl-4h-1,2-oxazole-5-carbonyl]-methylamino]-4-oxopentanoic acid Chemical compound O=C([C@H](CC(O)=O)N(C)C(=O)C1(ON=C(C1)[C@@H](NC(=O)C=1C2=CC=CC=C2C=CN=1)C(C)C)C=1C=CC=CC=1)COC(=O)C1=C(Cl)C=CC=C1Cl KVKFNHACKSHMOT-FJCNXOJISA-N 0.000 description 1
- KDMLNQFKKGCZRR-MBLJMWHHSA-N (3s)-5-(2,6-dichlorobenzoyl)oxy-3-[[3-[(1s)-2-methyl-1-(naphthalene-1-carbonylamino)propyl]-5-(phenoxymethyl)-4h-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2C3=CC=CC=C3C=CC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)COC1=CC=CC=C1 KDMLNQFKKGCZRR-MBLJMWHHSA-N 0.000 description 1
- ZESNYYAZPJWNGP-SUNKFUHCSA-N (3s)-5-(2,6-dichlorobenzoyl)oxy-3-[[3-[(1s)-2-methyl-1-(quinoline-2-carbonylamino)propyl]-5-(phenoxymethyl)-4h-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2N=C3C=CC=CC3=CC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)COC1=CC=CC=C1 ZESNYYAZPJWNGP-SUNKFUHCSA-N 0.000 description 1
- AKCTXNHOCISLEM-KWGQSPFMSA-N (3s)-5-(2,6-dichlorobenzoyl)oxy-3-[methyl-[3-[(1s)-2-methyl-1-(3-phenylpropanoylamino)propyl]-5-phenyl-4h-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound N([C@@H](C(C)C)C=1CC(ON=1)(C(=O)N(C)[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)C=1C=CC=CC=1)C(=O)CCC1=CC=CC=C1 AKCTXNHOCISLEM-KWGQSPFMSA-N 0.000 description 1
- ZLYZRLPZSUFLIP-PJXAABHXSA-N (3s)-5-(2,6-dichlorobenzoyl)oxy-3-[methyl-[3-[(1s)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-5-phenoxy-4h-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2C=C3C=CC=CC3=CC=2)C(C)C)=NOC1(C(=O)N(C)[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)OC1=CC=CC=C1 ZLYZRLPZSUFLIP-PJXAABHXSA-N 0.000 description 1
- NXTWVFVXVJRLSL-PJXAABHXSA-N (3s)-5-(2,6-dichlorobenzoyl)oxy-3-[methyl-[3-[(1s)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-5-phenyl-4h-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound O=C([C@H](CC(O)=O)N(C)C(=O)C1(ON=C(C1)[C@@H](NC(=O)C=1C=C2C=CC=CC2=CC=1)C(C)C)C=1C=CC=CC=1)COC(=O)C1=C(Cl)C=CC=C1Cl NXTWVFVXVJRLSL-PJXAABHXSA-N 0.000 description 1
- ZVUISQPAUMGPSL-YOGAAICWSA-N (3s)-5-(2,6-dichlorobenzoyl)oxy-3-[methyl-[3-[(1s)-2-methyl-1-(quinoline-2-carbonylamino)propyl]-5-phenyl-4h-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound O=C([C@H](CC(O)=O)N(C)C(=O)C1(ON=C(C1)[C@@H](NC(=O)C=1N=C2C=CC=CC2=CC=1)C(C)C)C=1C=CC=CC=1)COC(=O)C1=C(Cl)C=CC=C1Cl ZVUISQPAUMGPSL-YOGAAICWSA-N 0.000 description 1
- VOYMZPVGZVYQJV-JWFRVCKNSA-N (3s)-5-bromo-3-[[3-[(1s)-1-[3-(1h-indol-3-yl)propanoylamino]-2-methylpropyl]-5-phenyl-4h-1,2-oxazole-5-carbonyl]-methylamino]-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)CCC=2C3=CC=CC=C3NC=2)C(C)C)=NOC1(C(=O)N(C)[C@@H](CC(O)=O)C(=O)CBr)C1=CC=CC=C1 VOYMZPVGZVYQJV-JWFRVCKNSA-N 0.000 description 1
- PNBRNNKKGQRXJB-RXKSKBTASA-N (3s)-5-bromo-3-[methyl-[3-[(1s)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-5-phenyl-4h-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2C=C3C=CC=CC3=CC=2)C(C)C)=NOC1(C(=O)N(C)[C@@H](CC(O)=O)C(=O)CBr)C1=CC=CC=C1 PNBRNNKKGQRXJB-RXKSKBTASA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- ALZSTTDFHZHSCA-RNVDEAKXSA-N (4s)-4-[[(2s)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2s)-1-[[(2s)-3-carboxy-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC1=CC(=O)OC2=CC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(C)=O)C(C)C)=CC=C21 ALZSTTDFHZHSCA-RNVDEAKXSA-N 0.000 description 1
- ZMZRKOASUWINDA-VEABSNGSSA-N (4s)-4-[[(2s)-2-amino-3-carboxypropanoyl]amino]-5-[[(2s)-1-[[(2s)-1-carboxy-3-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)C[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O ZMZRKOASUWINDA-VEABSNGSSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 0 *C(*)(*)N(*)C(C(*)(C1)ON=C1C(*)(*)N*)=O Chemical compound *C(*)(*)N(*)C(C(*)(C1)ON=C1C(*)(*)N*)=O 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 description 1
- MRUDNSFOFOQZDA-UHFFFAOYSA-N 2,6-dichlorobenzoic acid Chemical compound OC(=O)C1=C(Cl)C=CC=C1Cl MRUDNSFOFOQZDA-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- OMXNKDLNBLDNDT-UHFFFAOYSA-N 2-naphthalen-2-yloxypentanoic acid Chemical compound C1=CC=CC2=CC(OC(CCC)C(O)=O)=CC=C21 OMXNKDLNBLDNDT-UHFFFAOYSA-N 0.000 description 1
- UOBYKYZJUGYBDK-UHFFFAOYSA-N 2-naphthoic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CC=C21 UOBYKYZJUGYBDK-UHFFFAOYSA-N 0.000 description 1
- KSRLFCGUHBVLJN-UHFFFAOYSA-N 2-oxo-5-phenoxypentanoic acid Chemical compound OC(=O)C(=O)CCCOC1=CC=CC=C1 KSRLFCGUHBVLJN-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- PVPJQOFXQKAELV-ZZHFZYNASA-N 3-[(1s)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-5-(phenoxymethyl)-4h-1,2-oxazole-5-carboxylic acid Chemical compound C1C([C@@H](NC(=O)C=2C=C3C=CC=CC3=CC=2)C(C)C)=NOC1(C(O)=O)COC1=CC=CC=C1 PVPJQOFXQKAELV-ZZHFZYNASA-N 0.000 description 1
- MHAVAHVWZBLHNG-AJZOCDQUSA-N 3-[(1s)-2-methyl-1-(phenylmethoxycarbonylamino)propyl]-5-(phenoxymethyl)-4h-1,2-oxazole-5-carboxylic acid Chemical compound N([C@@H](C(C)C)C=1CC(COC=2C=CC=CC=2)(ON=1)C(O)=O)C(=O)OCC1=CC=CC=C1 MHAVAHVWZBLHNG-AJZOCDQUSA-N 0.000 description 1
- YGLOALWHJIANIH-UHFFFAOYSA-N 3-[2-[[2-[[2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]propanoylamino]-4-[(4-methyl-2-oxochromen-7-yl)amino]-4-oxobutanoic acid Chemical compound C=1C=C2C(C)=CC(=O)OC2=CC=1NC(=O)C(CC(O)=O)NC(=O)C(C)NC(=O)C(C(C)C)NC(=O)C(NC(C)=O)CC1=CC=C(O)C=C1 YGLOALWHJIANIH-UHFFFAOYSA-N 0.000 description 1
- HGFGHLSWVYZKDC-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole-5-carboxylic acid Chemical compound OC(=O)C1CC=NO1 HGFGHLSWVYZKDC-UHFFFAOYSA-N 0.000 description 1
- KGNFQGZLKGFWQC-NNKBYCLSSA-N 4-O-tert-butyl 1-O-methyl (2S)-2-[[3-[(2S)-2-amino-3-methyl-1-oxo-1-phenylmethoxybutan-2-yl]-4,5-dihydro-1,2-oxazole-5-carbonyl]amino]butanedioate Chemical compound COC([C@H](CC(=O)OC(C)(C)C)NC(=O)C1CC(=NO1)[C@@](C(C)C)(C(=O)OCC1=CC=CC=C1)N)=O KGNFQGZLKGFWQC-NNKBYCLSSA-N 0.000 description 1
- GXWAKXFCMXDPPK-HKRAWCJGSA-N 4-O-tert-butyl 1-O-methyl (2S)-2-[methyl-[3-[(1S)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-5-phenoxy-4H-1,2-oxazole-5-carbonyl]amino]butanedioate Chemical compound COC([C@H](CC(=O)OC(C)(C)C)N(C(=O)C1(CC(=NO1)[C@H](C(C)C)NC(=O)C1=CC2=CC=CC=C2C=C1)OC1=CC=CC=C1)C)=O GXWAKXFCMXDPPK-HKRAWCJGSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- JFTCNBMROYPJQQ-RYZOHKRZSA-N 4-o-tert-butyl 1-o-methyl (2s)-2-[[5-benzyl-3-[(1s)-1-[1h-indol-3-yl(propanoyl)amino]-2-methylpropyl]-4h-1,2-oxazole-5-carbonyl]amino]butanedioate Chemical compound C1C([C@H](C(C)C)N(C(=O)CC)C=2C3=CC=CC=C3NC=2)=NOC1(C(=O)N[C@@H](CC(=O)OC(C)(C)C)C(=O)OC)CC1=CC=CC=C1 JFTCNBMROYPJQQ-RYZOHKRZSA-N 0.000 description 1
- AEMZVBSXTMZLRE-BOQWNVBCSA-N 4-o-tert-butyl 1-o-methyl (2s)-2-[[5-benzyl-3-[(1s)-2-methyl-1-(3-phenylprop-2-enoylamino)propyl]-4h-1,2-oxazole-5-carbonyl]amino]butanedioate Chemical compound C1C([C@@H](NC(=O)C=CC=2C=CC=CC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(=O)OC(C)(C)C)C(=O)OC)CC1=CC=CC=C1 AEMZVBSXTMZLRE-BOQWNVBCSA-N 0.000 description 1
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- ZZOKVYOCRSMTSS-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl carbamate Chemical compound C1=CC=C2C(COC(=O)N)C3=CC=CC=C3C2=C1 ZZOKVYOCRSMTSS-UHFFFAOYSA-N 0.000 description 1
- 108010021160 Ac-aspartyl-glutamyl-valyl-aspartyl-aminomethylcoumarin Proteins 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- GZRXRZHEDOOYRO-GVEDGAAKSA-N C1C([C@H](C(C)C)N(C(C)=O)C=2C3=CC=CC=C3NC=2)=NOC1(C(=O)N[C@@H](CC(=O)OC(C)(C)C)C(=O)OC)CC1=CC=CC=C1 Chemical compound C1C([C@H](C(C)C)N(C(C)=O)C=2C3=CC=CC=C3NC=2)=NOC1(C(=O)N[C@@H](CC(=O)OC(C)(C)C)C(=O)OC)CC1=CC=CC=C1 GZRXRZHEDOOYRO-GVEDGAAKSA-N 0.000 description 1
- QBSYFFOVXMJDJA-UCFFOFKASA-N CC([C@H](NC(CCC(=O)OC(C)(C)C)=O)C1=NOC(C1)(C(=O)OC)COC)C Chemical compound CC([C@H](NC(CCC(=O)OC(C)(C)C)=O)C1=NOC(C1)(C(=O)OC)COC)C QBSYFFOVXMJDJA-UCFFOFKASA-N 0.000 description 1
- CLMRJYGBKAICRG-DIMJTDRSSA-N CCC1(CC(=NO1)[C@H](C(C)C)NC(=O)CCC(=O)OC(C)(C)C)C(=O)OCC Chemical compound CCC1(CC(=NO1)[C@H](C(C)C)NC(=O)CCC(=O)OC(C)(C)C)C(=O)OCC CLMRJYGBKAICRG-DIMJTDRSSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000004068 Caspase-10 Human genes 0.000 description 1
- 108090000572 Caspase-10 Proteins 0.000 description 1
- 102100038916 Caspase-5 Human genes 0.000 description 1
- 101710090333 Caspase-5 Proteins 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- TULNGKSILXCZQT-UHFFFAOYSA-N Cysteinyl-Aspartate Chemical compound SCC(N)C(=O)NC(C(O)=O)CC(O)=O TULNGKSILXCZQT-UHFFFAOYSA-N 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102100038026 DNA fragmentation factor subunit alpha Human genes 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 229940089514 Fas agonist Drugs 0.000 description 1
- 206010061998 Hepatic lesion Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000012288 TUNEL assay Methods 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- GBJVAVGBSGRRKN-JYEBCORGSA-N Z-DEVD-FMK Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)OC)NC(=O)[C@H](CC(=O)OC)NC(=O)OCC1=CC=CC=C1 GBJVAVGBSGRRKN-JYEBCORGSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 231100000836 acute liver failure Toxicity 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- NMPVEAUIHMEAQP-UHFFFAOYSA-N alpha-bromo-acetaldehyde Natural products BrCC=O NMPVEAUIHMEAQP-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 108010051758 aspartyl-glutamyl-valyl-aspartal Proteins 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010799 enzyme reaction rate Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- PJMAUGGMECQITE-UHFFFAOYSA-N ethyl 2-(4-bromophenyl)prop-2-enoate Chemical compound CCOC(=O)C(=C)C1=CC=C(Br)C=C1 PJMAUGGMECQITE-UHFFFAOYSA-N 0.000 description 1
- ORRNHFXTIFQQIA-UHFFFAOYSA-N ethyl 2-(acetyloxymethyl)prop-2-enoate Chemical compound CCOC(=O)C(=C)COC(C)=O ORRNHFXTIFQQIA-UHFFFAOYSA-N 0.000 description 1
- SYGAXBISYRORDR-UHFFFAOYSA-N ethyl 2-(hydroxymethyl)prop-2-enoate Chemical compound CCOC(=O)C(=C)CO SYGAXBISYRORDR-UHFFFAOYSA-N 0.000 description 1
- FVLGPYFFONYLRZ-UHFFFAOYSA-N ethyl 2-benzylprop-2-enoate Chemical compound CCOC(=O)C(=C)CC1=CC=CC=C1 FVLGPYFFONYLRZ-UHFFFAOYSA-N 0.000 description 1
- OUGJKAQEYOUGKG-UHFFFAOYSA-N ethyl 2-methylidenebutanoate Chemical compound CCOC(=O)C(=C)CC OUGJKAQEYOUGKG-UHFFFAOYSA-N 0.000 description 1
- ILUCPNVXZDZFIT-UHFFFAOYSA-N ethyl 2-methylidenehexanoate Chemical compound CCCCC(=C)C(=O)OCC ILUCPNVXZDZFIT-UHFFFAOYSA-N 0.000 description 1
- MXUMJFMINXROCH-UHFFFAOYSA-N ethyl 2-methylidenepentanoate Chemical compound CCCC(=C)C(=O)OCC MXUMJFMINXROCH-UHFFFAOYSA-N 0.000 description 1
- IJBYVNFZITWYRD-UHFFFAOYSA-N ethyl 2-naphthalen-2-ylprop-2-enoate Chemical compound C1=CC=CC2=CC(C(=C)C(=O)OCC)=CC=C21 IJBYVNFZITWYRD-UHFFFAOYSA-N 0.000 description 1
- BGUDZGCMQVRTFT-ALLRNTDFSA-N ethyl 3-[(1s)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-5-(phenoxymethyl)-4h-1,2-oxazole-5-carboxylate Chemical compound C1C([C@@H](NC(=O)C=2C=C3C=CC=CC3=CC=2)C(C)C)=NOC1(C(=O)OCC)COC1=CC=CC=C1 BGUDZGCMQVRTFT-ALLRNTDFSA-N 0.000 description 1
- JFBDHSKKTHAZRP-XADRRFQNSA-N ethyl 3-[(1s)-2-methyl-1-(phenylmethoxycarbonylamino)propyl]-5-(phenoxymethyl)-4h-1,2-oxazole-5-carboxylate Chemical compound C1C([C@@H](NC(=O)OCC=2C=CC=CC=2)C(C)C)=NOC1(C(=O)OCC)COC1=CC=CC=C1 JFBDHSKKTHAZRP-XADRRFQNSA-N 0.000 description 1
- RSHXHCPBZUPENN-DJZRFWRSSA-N ethyl 3-[(1s)-2-methyl-1-[(2-methylpropan-2-yl)oxycarbonylamino]propyl]-5-pentyl-4h-1,2-oxazole-5-carboxylate Chemical compound CCCCCC1(C(=O)OCC)CC([C@@H](NC(=O)OC(C)(C)C)C(C)C)=NO1 RSHXHCPBZUPENN-DJZRFWRSSA-N 0.000 description 1
- HIZJURRUCIDWSM-DBUIHSHHSA-N ethyl 4-methyl-3-[(1S)-2-methyl-1-(2-phenylpropanoylamino)propyl]-5-phenyl-4H-1,2-oxazole-5-carboxylate Chemical compound C1(=CC=CC=C1)C(C)C(=O)N[C@@H](C(C)C)C1=NOC(C1C)(C(=O)OCC)C1=CC=CC=C1 HIZJURRUCIDWSM-DBUIHSHHSA-N 0.000 description 1
- HDCOLTJVOSOASB-YSJWXEPDSA-N ethyl 4-methyl-3-[(1s)-2-methyl-1-[(2-methylpropan-2-yl)oxycarbonylamino]propyl]-5-phenoxy-4h-1,2-oxazole-5-carboxylate Chemical compound C=1C=CC=CC=1OC1(C(=O)OCC)ON=C([C@@H](NC(=O)OC(C)(C)C)C(C)C)C1C HDCOLTJVOSOASB-YSJWXEPDSA-N 0.000 description 1
- XXFWGNAMDHTYIL-PIVQAISJSA-N ethyl 5-(acetyloxymethyl)-3-[(1s)-2-methyl-1-[(2-methylpropan-2-yl)oxycarbonylamino]propyl]-4h-1,2-oxazole-5-carboxylate Chemical compound CCOC(=O)C1(COC(C)=O)CC([C@@H](NC(=O)OC(C)(C)C)C(C)C)=NO1 XXFWGNAMDHTYIL-PIVQAISJSA-N 0.000 description 1
- HVKSXPKRBGIJAX-XADRRFQNSA-N ethyl 5-benzyl-3-[(1s)-2-methyl-1-(phenylmethoxycarbonylamino)propyl]-4h-1,2-oxazole-5-carboxylate Chemical compound C1C([C@@H](NC(=O)OCC=2C=CC=CC=2)C(C)C)=NOC1(C(=O)OCC)CC1=CC=CC=C1 HVKSXPKRBGIJAX-XADRRFQNSA-N 0.000 description 1
- KQQSTOCODYIGEJ-HXBUSHRASA-N ethyl 5-benzyl-3-[(1s)-2-methyl-1-[(2-methylpropan-2-yl)oxycarbonylamino]propyl]-4h-1,2-oxazole-5-carboxylate Chemical compound C=1C=CC=CC=1CC1(C(=O)OCC)CC([C@@H](NC(=O)OC(C)(C)C)C(C)C)=NO1 KQQSTOCODYIGEJ-HXBUSHRASA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000005373 execution phase of apoptosis Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000001951 hemoperfusion Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 108010035817 human DNA fragmentation factor Proteins 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000019189 interleukin-1 beta production Effects 0.000 description 1
- 108010027775 interleukin-1beta-converting enzyme inhibitor Proteins 0.000 description 1
- 239000011872 intimate mixture Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000013038 irreversible inhibitor Substances 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 150000002545 isoxazoles Chemical class 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Inorganic materials [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- ZXRPQWHVIZSPFK-LURJTMIESA-N methyl (3s)-4-chloro-4-hydroxyimino-3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate Chemical compound COC(=O)C[C@@H](C(Cl)=NO)NC(=O)OC(C)(C)C ZXRPQWHVIZSPFK-LURJTMIESA-N 0.000 description 1
- QBWGSUXSXLLRIP-QASNXKAYSA-N methyl 3-[(1s)-1-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutyl]-5-methyl-4h-1,2-oxazole-5-carboxylate Chemical compound O1C(C(=O)OC)(C)CC([C@H](CCC(=O)OC(C)(C)C)NC(=O)OCC2C3=CC=CC=C3C3=CC=CC=C32)=N1 QBWGSUXSXLLRIP-QASNXKAYSA-N 0.000 description 1
- WXPPJLGLPLMWBE-HKALDPMFSA-N methyl 5-(methoxymethyl)-3-[(1s)-2-methyl-1-[(2-methylpropan-2-yl)oxycarbonylamino]propyl]-4h-1,2-oxazole-5-carboxylate Chemical compound COCC1(C(=O)OC)CC([C@@H](NC(=O)OC(C)(C)C)C(C)C)=NO1 WXPPJLGLPLMWBE-HKALDPMFSA-N 0.000 description 1
- OAWLVKADJFAZNK-UCFFOFKASA-N methyl 5-methyl-3-[(1s)-2-methyl-1-[[5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]amino]propyl]-4h-1,2-oxazole-5-carboxylate Chemical compound COC(=O)C1(C)CC([C@@H](NC(=O)CCCC(=O)OC(C)(C)C)C(C)C)=NO1 OAWLVKADJFAZNK-UCFFOFKASA-N 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 1
- IYTLZVVFAZPKLY-UHFFFAOYSA-N n-(1h-indol-3-yl)propanamide Chemical compound C1=CC=C2C(NC(=O)CC)=CNC2=C1 IYTLZVVFAZPKLY-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- RMHJJUOPOWPRBP-UHFFFAOYSA-N naphthalene-1-carboxamide Chemical compound C1=CC=C2C(C(=O)N)=CC=CC2=C1 RMHJJUOPOWPRBP-UHFFFAOYSA-N 0.000 description 1
- JVXXKQIRGQDWOJ-UHFFFAOYSA-N naphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(C(=O)N)=CC=C21 JVXXKQIRGQDWOJ-UHFFFAOYSA-N 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000013037 reversible inhibitor Substances 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000001577 simple distillation Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000004544 spot-on Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- DYWOMJIGQSCLMK-SNVBAGLBSA-N tert-butyl (2S)-2-amino-2-(C-chloro-N-hydroxycarbonimidoyl)-3-methylbutanoate Chemical compound C(C)(C)(C)OC(=O)[C@](C(=NO)Cl)(C(C)C)N DYWOMJIGQSCLMK-SNVBAGLBSA-N 0.000 description 1
- JFGJGQNSFXHKAB-MRVPVSSYSA-N tert-butyl N-[(2S)-1-hydroxyimino-3-methylbutan-2-yl]carbamate Chemical compound CC(C)[C@H](NC(=O)OC(C)(C)C)C=NO JFGJGQNSFXHKAB-MRVPVSSYSA-N 0.000 description 1
- YMNBXYLOSIKZGL-MRVPVSSYSA-N tert-butyl n-[(2s)-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound CC(C)[C@@H](C=O)NC(=O)OC(C)(C)C YMNBXYLOSIKZGL-MRVPVSSYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR1999/000561 WO2001021599A1 (en) | 1999-09-17 | 1999-09-17 | Caspase inhibitor |
| WOPCT/KR99/00561 | 1999-09-17 | ||
| KR10-1999-0048608A KR100399361B1 (ko) | 1999-11-04 | 1999-11-04 | 캐스파제 억제제 함유 치료제 조성물 |
| KR9948608 | 1999-11-04 | ||
| PCT/KR2000/001047 WO2001021600A1 (en) | 1999-09-17 | 2000-09-18 | Caspase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60013147D1 DE60013147D1 (en) | 2004-09-23 |
| DE60013147T2 true DE60013147T2 (de) | 2005-08-11 |
Family
ID=26634563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60013147T Expired - Lifetime DE60013147T2 (de) | 1999-09-17 | 2000-09-18 | Caspase-hemmer |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1212309B1 (https=) |
| JP (1) | JP4195561B2 (https=) |
| CN (1) | CN1137888C (https=) |
| AT (1) | ATE273705T1 (https=) |
| AU (1) | AU7322300A (https=) |
| CA (1) | CA2388564C (https=) |
| DE (1) | DE60013147T2 (https=) |
| WO (1) | WO2001021600A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100399361B1 (ko) * | 1999-11-04 | 2003-09-26 | 주식회사 엘지생명과학 | 캐스파제 억제제 함유 치료제 조성물 |
| US7026111B2 (en) * | 2001-10-15 | 2006-04-11 | Beckman Coulter, Inc. | Methods and reagents for improved cell-based assays |
| KR100594544B1 (ko) * | 2003-08-27 | 2006-06-30 | 주식회사 엘지생명과학 | 이소옥사졸린 구조를 갖는 캐스파제 저해제 |
| KR100774999B1 (ko) | 2005-02-26 | 2007-11-09 | 주식회사 엘지생명과학 | 이소옥사졸린 유도체 및 그의 제조 방법 |
| EP1746167A1 (en) * | 2005-07-20 | 2007-01-24 | Apoxis SA | Method for the identification of compounds susceptible to inhibit inflammation |
| WO2009013293A1 (en) * | 2007-07-24 | 2009-01-29 | Novartis Ag | Substituted cyclohexanecarboxamides useful as bace inhibitors |
| KR20090099886A (ko) * | 2008-03-18 | 2009-09-23 | 주식회사 엘지생명과학 | 캐스파제 저해제의 프로드럭 |
| WO2019030574A1 (en) | 2017-08-10 | 2019-02-14 | Cerenis Therapeutics Holding | Cargomers |
| TWI906428B (zh) * | 2020-12-10 | 2025-12-01 | 南韓商Lg化學股份有限公司 | 酸(Boronic Acid)化合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995014680A1 (en) * | 1993-11-26 | 1995-06-01 | Pfizer Inc. | 3-aryl-2-isoxazolines as antiinflammatory agents |
| ATE154932T1 (de) * | 1993-11-26 | 1997-07-15 | Pfizer | Isoxazolinverbindungen als entzündungshemmende mittel |
| ATE169009T1 (de) * | 1994-03-09 | 1998-08-15 | Pfizer | Isoxazoline verbindung zur hemmung tnf-freigabe |
| NZ334906A (en) * | 1996-10-11 | 2000-09-29 | Basf Ag | A sulphonamido pentanoic acid derivative useful as an interleukin-1-beta converting enzyme inhibitor |
| JPH11180891A (ja) * | 1997-12-25 | 1999-07-06 | Dai Ichi Seiyaku Co Ltd | 抗細胞死剤 |
| KR100373375B1 (ko) * | 1998-04-03 | 2003-06-12 | 주식회사 엘지생명과학 | 인터루킨-1b-컨버팅효소및아포파인/cpp-32에대한저해제 |
| WO2001021599A1 (en) * | 1999-09-17 | 2001-03-29 | Lg Chemical Ltd. | Caspase inhibitor |
-
2000
- 2000-09-18 DE DE60013147T patent/DE60013147T2/de not_active Expired - Lifetime
- 2000-09-18 AU AU73223/00A patent/AU7322300A/en not_active Abandoned
- 2000-09-18 CN CNB008137056A patent/CN1137888C/zh not_active Expired - Fee Related
- 2000-09-18 AT AT00961242T patent/ATE273705T1/de not_active IP Right Cessation
- 2000-09-18 CA CA002388564A patent/CA2388564C/en not_active Expired - Fee Related
- 2000-09-18 EP EP00961242A patent/EP1212309B1/en not_active Expired - Lifetime
- 2000-09-18 JP JP2001524979A patent/JP4195561B2/ja not_active Expired - Fee Related
- 2000-09-18 WO PCT/KR2000/001047 patent/WO2001021600A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2388564A1 (en) | 2001-03-29 |
| EP1212309A4 (en) | 2002-11-27 |
| DE60013147D1 (en) | 2004-09-23 |
| WO2001021600A1 (en) | 2001-03-29 |
| JP2003509502A (ja) | 2003-03-11 |
| AU7322300A (en) | 2001-04-24 |
| EP1212309A1 (en) | 2002-06-12 |
| EP1212309B1 (en) | 2004-08-18 |
| CA2388564C (en) | 2007-11-06 |
| CN1377344A (zh) | 2002-10-30 |
| CN1137888C (zh) | 2004-02-11 |
| ATE273705T1 (de) | 2004-09-15 |
| JP4195561B2 (ja) | 2008-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69517196T2 (de) | Inhibitoren der menschlichen neutrophilenelastase | |
| KR100197306B1 (ko) | 면역억제 화합물 | |
| DE69713109T2 (de) | Verbindungen mit wachstumshormon freisetzenden eigenschaften | |
| DE69622840T2 (de) | Hydroxylamin derivate verwendbar für die verbesserung der erzeugung von molekularen kappen und deren herstellung | |
| MC2040A1 (fr) | Derives d'acides amines | |
| WO1993003013A1 (fr) | Derives d'indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant | |
| EP1169338A2 (de) | Niedermolekulare inhibitoren von komplementproteasen | |
| EA005740B1 (ru) | Карбаматные ингибиторы каспазы и их использование | |
| CZ63199A3 (cs) | Sloučeniny typu substituovaných cyklických aminů jako inhibitory metaloproteáz, způsob jejich přípravy a použití jako léčiv | |
| AU2002225767A1 (en) | Bisubstituted carbocyclic cyclophilin binding compounds and theirus | |
| DE60013147T2 (de) | Caspase-hemmer | |
| EP0344682B1 (de) | Oligopeptide mit zyklischen Prolin-analogen Aminosäuren | |
| FR2515182A1 (fr) | Nouveaux produits derives de l'acide 3-amino 2-oxo azetidine 1-sulfamique, leur procede de preparation, leur application comme medicaments et les produits intermediaires necessaires a leur preparation | |
| AU2005219861B2 (en) | Caspase inhibitors and uses thereof | |
| DE69718469T2 (de) | Verbindungen mit wachtumshormon freisetzenden eigenschaften | |
| DE3782191T2 (de) | Difluorketoverbindungen. | |
| US6747050B1 (en) | Isoxazoline derivative and a process for the preparation thereof | |
| TWI840723B (zh) | 吡咯衍生物及製備方法和用途 | |
| ZA200202148B (en) | Caspase inhibitor. | |
| DE4026614A1 (de) | Phosphonopyrrolidin- und piperidin-haltige pseudopeptide vom statintyp, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel gegen retroviren | |
| JP2001500853A (ja) | 医薬化合物 | |
| EP0310015A2 (de) | Renin-hemmende Dipeptide, Verfahren zu deren Herstellung, diese enthaltende Mittel und ihre Verwendung | |
| CH659475A5 (fr) | Composes peptidiques substitues et compositions pharmaceutiques les contenant. | |
| WO1998022443A1 (fr) | Derives de n-(imidazolylbutyle) benzenesulfonamide ayant une activite antithrombotique | |
| FR2725992A1 (fr) | Peptide antifongique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |